NovoCure NVCR Ratios & Valuation
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 75.2%+0.7pp | 74.5%-0.8pp | 75.4%-1.0pp | 76.4%-0.8pp | 77.2%-0.2pp | |
| Operating margin | -27.2%-3.7pp | -23.5%+4.0pp | -27.5%-0.1pp | -27.4%-0.6pp | -26.8%+1.3pp | |
| Net margin | -25.7%-4.9pp | -20.8%+6.9pp | -27.7%-0.5pp | -27.1%-0.7pp | -26.4%+1.5pp | |
| EBITDA margin | -24.9%-3.7pp | -21.2%+4.2pp | -25.4%+0.1pp | -25.5%-0.5pp | -24.9%+1.4pp | |
| Free cash flow margin | -7.1%+4.4pp | -11.5%-1.4pp | -10.1%+2.6pp | -12.8%-1.2pp | -11.6%-0.2pp | |
| Returns | ||||||
| Return on equity | -50%-11.1pp | -38.9%+11.7pp | -50.6%-2.5pp | -48.1%-2.6pp | -45.5%+1.1pp | |
| Return on assets | -17%-3.7pp | -13.3%+0.4pp | -13.8%+0.2pp | -13.9%-0.1pp | -13.9%+0.3pp | |
| Return on invested capital | -65.8%-7.1pp | -58.6%+89.6pp | -148.2%-73.3pp | -74.9%-31.9pp | -43%-7.1pp | |
| Efficiency | ||||||
| Asset turnover | 0.7×0.0× | 0.6×+0.1× | 0.5×0.0× | 0.5×0.0× | 0.5×0.0× | |
| Inventory turnover | 4×-0.3× | 4.4×+0.3× | 4×+0.4× | 3.7×+0.2× | 3.5×-0.3× | |
| Liquidity | ||||||
| Current ratio | 2.9×0.0× | 2.9×+1.4× | 1.5×+0.1× | 1.4×0.0× | 1.5×0.0× | |
| Quick ratio | 2.7×0.0× | 2.7×+1.2× | 1.5×+0.1× | 1.4×0.0× | 1.4×0.0× | |
| Cash ratio | 0.4×0.0× | 0.4×0.0× | 0.4×+0.2× | 0.2×0.0× | 0.2×0.0× | |
| Leverage | ||||||
| Debt-to-equity | 0.1×0.0× | 0.2×0.0× | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | |
| Debt-to-assets | 0.1×0.0× | 0.1×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | |
| Interest coverage | -21.1×-12.6× | -8.5×-1.7× | -6.7×-1.1× | -5.6×-1.1× | -4.5×-0.2× | |
| Per Share | ||||||
| Book value per share | $2.90-5.1% | $3.05+0.1% | $3.05-2.6% | $3.13-4.6% | $3.28-1.7% | |
| Valuation | ||||||
| Market capitalization | $1.24B-14.3% | $1.45B+0.2% | $1.44B-23.8% | $1.9B-3.2% | $1.96B-39.3% | |
| Enterprise value | $1.19B-15.3% | $1.41B+22.9% | $1.15B-36.0% | $1.79B-4.4% | $1.87B-39.4% | |
| Price / sales | 1.8×-0.4× | 2.2×0.0× | 2.2×-0.8× | 3×-0.1× | 3.2×-2.2× | |
| Price / book | 3.8×-0.5× | 4.3×0.0× | 4.2×-1.2× | 5.4×0.0× | 5.4×-3.5× | |
| EV / sales | 1.8×-0.4× | 2.1×+0.4× | 1.8×-1.1× | 2.8×-0.2× | 3×-2.1× | |
| Free cash flow yield | -3.9%+1.4pp | -5.2%-0.7pp | -4.5%-0.3pp | -4.2%-0.6pp | -3.7%-1.5pp | |
| Earnings yield | -14%-4.5pp | -9.4%+2.9pp | -12.3%-3.3pp | -9%-0.6pp | -8.4%-3.2pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are NovoCure's profit margins?
- NovoCure (NVCR) runs a 75.2% gross margin and a -27.2% operating margin, with a -25.7% net margin.
- Where do NovoCure's ratios come from?
- Every ratio is computed from NovoCure's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
